29 results about "Phagocytic Cell" patented technology

Provided herein is a nucleic acid detection system comprising a detection CRISPR system having an effector protein and one or more guide RNAs each designed to bind to corresponding target molecules that are diagnostic for a tick-borne disease state; and an RNA-based masking construct. In some embodiments, the detection system of may comprise i) two or more CRISPR systems, each CRISPR system comprising an effector protein and a guide RNA designed to bind to a corresponding target molecule that is diagnostic for a tick-borne disease state; and ii) a set of detection constructs, each detection construct comprising a cutting motif sequence that is preferentially cut by one of the activated CRISPR effector proteins. Exemplary tick-borne detectable microbes include Babesia microti, Anaplasma phagocytophilum, and Borrelia miyamotoi.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

The invention discloses a coupling molecule with an effect of promoting macrophages to selectively swallow extracellular goods as well as a preparation method and application of the coupling molecule, and belongs to the technical field of biological medicines. The coupling molecule disclosed by the invention is a double-targeting polypeptide and consists of a macrophage targeting peptide fragment, a linker and a target cell targeting peptide fragment, wherein the target cell targeting peptide fragment comprises peptide fragments targeting tumor cells and apoptotic cells. One end of the dual-targeting polypeptide is connected with macrophages, the other end of the dual-targeting polypeptide is connected with tumor cells / apoptotic cells, and the interaction between the macrophages and the tumor cells / apoptotic cells is improved in a molecular glue mode. Aiming at tumor cells, the dual-targeting polypeptide can enhance the phagocytosis and killing effects of macrophages on the tumor cells under the action of a CD47 antibody, so that the anti-tumor effect is achieved; aiming at apoptotic cells, the dual-targeting polypeptide can promote the interplant effect of macrophages, so that the anti-inflammatory effect is achieved. Therefore, the dual-targeting polypeptide disclosed by the invention has relatively good drug development potential.

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.

Compositions and methods for preparing and using engineered phagocytes expressing chimeric antigen receptors with enhanced phagocytic activity are described, and the compositions and methods may be suitable for immunotherapy in cancer or infection.

The application discloses a CXCL-BPI fusion protein which can be used for treating gram-negative bacterial infection, a coding nucleic acid of the CXCL-BPI fusion protein, an expression preparation method, and application of the CXCL-BPI fusion protein to preparation of a pharmaceutical composition for treating gram-negative bacterial infection. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a human BPI N-terminal domain functional fragment, has the functions of combining LPS, directly killing gram-negative bacteria and chemotactic cell migration, and also has the functions of promoting phagocytes to be guided to combine and phagocytize gram-negative bacteria, and the action mechanism can overcome gram-negative bacterial drug resistance.

The invention relates to methods of evaluating phagocytosis at a single-cell level by placing one or more phagocytes and one or more particles on a surface and visualizing the phagocytosis of the particles by the phagocytes. The invention also relates to systems for evaluating phagocytosis of a particle by a phagocyte at a single-cell level.

A method for estimating a number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive dioxygenation of a chemiluminigenic substrate by an emitted chemiluminescence of the chemiluminigenic substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes. The NADPH oxidase activity of the phagocytes is preferably stimulated by a stimulus in solution or coated to a surface contacted by the phagocytes. The stimulus is preferably phorbol myristate acetate (PMA). The animal is preferably human, and the body fluid is preferably blood and / or spinal fluid. The phagocytes are preferably neutrophil leukocytes, and the chemiluminigenic substrate is preferably lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of treatment based on the estimation method.

The present invention provides attenuated immunostimulatory bacteria whose genome is modified to, for example, reduce toxicity and increase anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor-resident myeloid cells, increasing resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T cell function. The increase in phagocyte colonization improves delivery of encoded therapeutic products to the tumor microenvironment and into the tumor, and allows for routes of immunostimulatory bacteria administration such as systemic administration.

The present application relates to a kind of drug combination products for enhancing the therapeutic effect of nanomedicine, belong to nanomedicine technical field.The drug combination product includes following (1), (2) and (3): (1) stimulus-responsive nanomedicine;(2) mononuclear phagocyte system blocker;(3) exogenous reducing substance.The drug combination product provided by the present application carries out the regulation in time sequence to the in vivo delivery and release process of nanomedicine by "first block then loose" delivery strategy, realizes the effective accumulation and intelligent release of nanomedicine in target tissue, to improve the therapeutic effect.

A product comprises: (a) a vector for specific expression of liver and / or spleen phagocytes, wherein the vector comprises a transgene operably linked to one or more expression control sequences; and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.

The phagocytic cell AI identification training, detection and proportion detection analysis method comprises the following steps: preprocessing a sample to obtain a microscopic sample; shooting a microscopic examination sample to obtain a microscopic examination sample image; identifying and labeling phagocytic cells in the microscopic examination sample image to obtain a phagocytic cell labeling picture; and AI training is carried out by using the labeled picture to obtain an AI identification feature data set A, and the AI identification feature data set A comprises phagocytic cell AI identification feature data. Identifying the microscopic examination sample image by using an AI identification algorithm, identifying phagocytic cells in hydrothorax and ascites in a selected area S1 of the image, obtaining the number NUM1 of the phagocytic cells, and obtaining the number NUM2 of phagocytic cells; in a microscopic examination sample, the content of phagocytic cells in unit volume is equal to NUM1 / V1. The ratio of phagocytic cells is equal to NUM1 / NUM2.

The present invention provides a method for producing cells polarized to the M2 phenotype, said method comprising culturing mononuclear phagocyte system cells in a suitable medium comprising lactic acid or a lactic acid derivative, and subjecting said cells to a period of hypoxia followed by a period of reoxygenation. The present invention also provides compositions comprising cells obtained with the method as defined herein and uses thereof.

The present disclosure relates to a novel biomarker of a liver condition. Specifically, the present disclosure provides a method of identifying subjects with or at risk of developing liver inflammation and / or liver disease, and uses of a marker indicative of liver inflammation and / or liver disease. There is also provided a modulator for use in the treatment and / or prevention of liver inflammation and / or liver disease.

Provided are a GAS6 fusion protein, a preparation method therefor and the use thereof. The provided fusion protein contains an scFv capable of specifically recognizing tumor cell antigens, and can disguise tumor cells as apoptotic cells and enable phagocytosis of tumor cells by phagocytes by means of interaction with TAM RTK. The provided GAS6 fusion protein is applicable for phagocytosis of various tumor cells, showing strong broad-spectrum properties.

A chemiluminescence-based method for quantifying the number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive dioxygenation of a chemiluminescent substrate by an emitted chemiluminescence of the chemiluminescent substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes. The phagocytes are preferably neutrophil leukocytes, and the chemiluminescent substrate is preferably lucigenin (N, N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of measuring myeloperoxidase activity of the neutrophils present in a sample of blood or body fluid based on the non-reductive (simple) dioxygenation of a chemiluminescent substrate, preferably luminol (5-amino-2,3-dihydro-1,4-phthalazinedione). The methods use dual chemiluminescent probes on microvolumes of blood or body fluid to enable reliable optical measurements applicable to point-of-care testing.

Provided is a method for determining phagocytosis capacity of phagocytes, comprising: obtaining a phagocyte image and a target cell image, the phagocyte image and the target cell image being extracted from high-content images obtained by photographing co-cultured phagocytes and target cells; decomposing the target cell image into a plurality of sub-band images, each sub-band image comprising pixels of the target cell image having luminance values falling into a corresponding luminance sub-band of a plurality of luminance sub-bands, the plurality of luminance sub-bands being obtained by dividing a luminance range of pixels of the target cell image; determining respective numbers of target cell objects contained in the plurality of sub-band images; determining a number of phagocytes contained in the phagocyte image; and determining phagocytosis capacity of the phagocytes on the target cells based on the respective numbers of target cell objects contained in the plurality of sub-band images and the number of phagocytes contained in the phagocyte image.

An exemplary embodiment of the present disclosure provides a method for diagnostic imaging including, labeling a phagocytotic cell with an echogenic microbubble, introducing the labeled phagocytotic cell into a patient, and ultrasound imaging the patient to determine a location of the labeled phagocytotic cell in the patient.

Amyloid-binding constructs, including antibodies, bispecific molecules, and chimeric antigen receptors, are provided for diagnosing or treating AL amyloidosis. Also provided are methods of detecting or reducing light chain amyloid fibril deposits in an organ of a subject.

A method for estimating a number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive dioxygenation of a chemiluminigenic substrate by an emitted chemiluminescence of the chemiluminigenic substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes. The NADPH oxidase activity of the phagocytes is preferably stimulated by a stimulus in solution or coated to a surface contacted by the phagocytes. The stimulus is preferably phorbol myristate acetate (PMA). The animal is preferably human, and the body fluid is preferably blood and / or spinal fluid. The phagocytes are preferably neutrophil leukocytes, and the chemiluminigenic substrate is preferably lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of treatment based on the estimation method.

Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.

Amyloid-binding constructs, including antibodies, bispecific molecules, and chimeric antigen receptors, are provided for diagnosing or treating AL amyloidosis. Also provided are methods of detecting or reducing light chain amyloid fibril deposits in an organ of a subject.

Amyloid-binding constructs, including antibodies, bispecific molecules, and chimeric antigen receptors, are provided for diagnosing or treating AL amyloidosis. Also provided are methods of detecting or reducing light chain amyloid fibril deposits in an organ of a subject.

The present invention relates to compositions and methods that provide novel therapies in cancer. The invention includes a phagocytic cell modified with a repressor of signal regulatory protein-alpha (SIRPα) and bound to a targeting antibody to enhance phagocytic activity of the phagocytic cell toward tumor tissue. Methods of enhancing phagocytic activity and treating a tumor are also included.

The invention relates to a neurotrophic factor nano delivery system capable of shielding NETs and application of the neurotrophic factor nano delivery system, and belongs to the technical field of biological medicine. The preparation method comprises the following steps: carrying out reversible modification on positively charged BDNF through ATP (adenosine triphosphate) to obtain negatively charged A-BDNF; the method comprises the following steps: treating microglial cells by using LPS to obtain a microglial cell membrane with high expression of polysialic acid, and coating A-BDNF by using PBM to obtain A-BDNF (at) PBM NPs. The A-BDNF (at) PBM NPs can be effectively enriched at a damaged spinal cord part, and is combined with NETs through high-expression polysialic acid on the surface of the PBM to trigger the PBM to fall off, so that PS positioned on cytoplasm lobules of the PBM is exposed on the surfaces of the NETs, and the PS serves as a'eating my 'signal to enable phagocytes to remove the NETs through an interburial effect and trigger a neuroprotective immune response. Meanwhile, the released A-BDNF is recovered to BDNF in a subacid environment, and nerve regeneration is promoted.

This invention discloses an active ingredient from Huzhou sheep and its application in immunomodulatory health products, belonging to the field of immunomodulatory agent technology. Specifically, it relates to an active ingredient from Huzhou sheep, comprising Huzhou sheep placental extract and methyl galbaceous oxalate, with a mass ratio of 1:0.11-0.23. The Huzhou sheep active ingredient disclosed in this invention can effectively scavenge free radicals, reduce oxidative stress levels, and improve antioxidant capacity. Simultaneously, it enhances the positive regulation of phagocytic activity of phagocytes, thereby enhancing immune function and demonstrating good application value in immunomodulatory agents.

The invention discloses a construction method of an atherosclerotic advanced vulnerable plaque rapid modeling gene mouse, and belongs to the technical field of biology. According to the method, an apolipoprotein E gene (apolipoprotein E, ApoE) knockout mouse which does not need to be subjected to induction and is specifically knocked out from an insulin-like growth factor 1 (IGF1) gene tissue is obtained through a hybridization method and a Cre-LoxP technology. According to the invention, a mononuclear phagocyte system specific knockout IGF1 gene is introduced into an ApoE- / -mouse genome for the first time, the characteristics of two genotypes are combined, and atherosclerotic advanced vulnerable plaque with the characteristics of large lipid core, a large number of inflammatory cells, typical thin fibrous caps, negative vascular remodeling and the like can be formed without induction; and the method is simple and easy to implement and good in repeatability, and the molding time is shortened.

A novel cytokine-derived cell penetrating peptide and use thereof are provided. The cell penetrating peptide has the ability to effectively deliver a biologically active substance into phagocytes, particularly macrophages, both in vitro and in vivo. The cell penetrating peptide can deliver a biologically active substance into macrophages with high efficiency compared to TAT peptide and dNP2 peptide that are commercially available as cell penetrating peptides.

An organism comprising (a) a vector for phagocytic cell-specific expression of the liver and / or spleen, wherein the vector comprises a transgene operably linked to one or more expression regulatory sequences, and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.